Alkem Laboratories logo

Alkem Laboratories

ALKEM NSE

Key Fundamentals

MidcapPharmaceuticalsHealthcare
Market Cap
₹60,655 Cr
Volatility
Moderate
P/E Ratio
28.19
EBITDA
₹3,589 Cr
Return on Equity
16.4%
Debt to Equity
0.15
Book Value
₹1,155.87
EPS
₹179.8
52W High
₹5,933.5
52W Low
₹5,075

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 26.3%

Weaknesses

2
  • Promoter holding has decreased over last quarter: -1.50%
  • The company has delivered a poor sales growth of 10.7% over past five years.

Growth Rate

Revenue Growth
13.65% higher than 3Y
Net Income Growth
6.19% lower than 3Y
Cash Flow Change
2.62% higher than 3Y
ROE
-7.97% lower than 3Y
ROCE
-2.33% lower than 3Y
EBITDA Margin (Avg.)
5.06% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
AI opinion · based on fundamentals
Risk medium

Alkem Laboratories trades at a market cap of ₹60,655 Cr with a P/E of 27.7x and a consistent ROE of ~19% over the last three years. TTM sales growth has accelerated to 13%, though TTM profit growth has stalled at 0%, and the stock has declined 5% over the past year.

Bull Case 7
  • Consistent return on equity of 19% over the last year and 18-19% across 3, 5, and 10-year periods, indicating durable capital efficiency
  • TTM revenue growth of 13% marks an acceleration from the 8% compounded sales growth over the past 3 years
  • Strong 3-year compounded profit growth of 32%, reflecting significant margin expansion over that period
  • 10-year compounded sales CAGR of 12% and profit CAGR of 12% demonstrate a long track record of balanced top-line and bottom-line growth
  • Healthy dividend payout ratio of 26.3% with a current dividend yield of 1.03%, providing some income return to shareholders
  • P/B ratio of 4.42x is supported by the sustained 18-19% ROE, suggesting the premium is backed by earnings quality
  • 10-year stock CAGR of 12% has broadly tracked the underlying earnings compounding, showing reasonable long-term price discovery
Bear Case 7
  • TTM profit growth has flatlined at 0% despite 13% revenue growth, signaling margin compression in the most recent period
  • Stock has delivered a negative 1-year return of -5%, underperforming the broader market
  • Promoter holding decreased by 1.50% in the last quarter, which may signal reduced insider confidence
  • 5-year compounded sales growth of only 10.7-11% is considered below par for a mid-to-large cap pharma company
  • P/E of 27.7x is elevated relative to the 0% TTM profit growth, leaving limited room for execution misses
  • 5-year stock CAGR of just 6% suggests the market has re-rated the stock downward over the medium term despite earnings growth
  • 5-year compounded profit growth of only 9% lags the 3-year figure of 32%, indicating the strong profit growth is a recent and potentially unsustainable trend

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 2h ago
Headwinds 2
  • Q1 profit drops 22% on taxes Aug 20

    Consolidated net profit fell 21.7% to ₹5,200 million in Q1FY27 due to new tax regime adoption and EBITDA margin compression, despite 10.9% revenue growth to ₹37,402 million.

  • CDMO unit burning ₹60Cr/quarter Aug 20

    US CDMO unit (Enzene BioSciences) incurring ₹60 crore in quarterly expenses as it ramps up, with breakeven expected only in the next 4-8 quarters.

Positives 4
  • Elara initiates Buy, ₹6,533 target Sep 01

    Elara Securities initiated a BUY rating with a ₹6,533 target price (26.5x FY29E core earnings), implying significant upside from the ₹5,300 CMP. Key catalysts include semaglutide entry and upcoming gJynarque (Tolvaptan) US launch.

  • Patented hair growth serum launched Sep 08

    Alkem launched Renocia Exo, India's first patented Ginsenoside Exosome-based hair growth serum, expanding its specialty consumer health portfolio.

  • International sales surge 16% Aug 20

    International sales grew 16.0% in Q1FY27 led by non-US markets, while domestic branded generics grew 12%, outperforming the Indian pharma market by 100 bps.

  • Adroit Biomed merger approved Aug 17

    Shareholders approved the amalgamation scheme with Adroit Biomed Limited by 99.9999% margin, strengthening Alkem's MedTech and orthopaedics franchise.

Neutral 2
  • 52nd AGM resolutions all passed Aug 27

    Shareholders approved all resolutions at the August 27 AGM including FY26 financials, dividend declaration, and board re-appointments.

  • HDFC MF crosses 5% stake Aug 26

    HDFC Mutual Fund increased aggregate holding to 5.017% as of August 24, 2026, crossing the disclosure threshold via open market purchases.

TL;DR: Alkem is executing a broad diversification strategy across chronic therapies, MedTech, biologics CDMO, and international markets, with strong domestic growth outpacing the industry. The key risk is near-term earnings pressure from tax regime changes and loss-making CDMO/MedTech investments compressing margins. Elara's ₹6,533 target and 16% international growth signal confidence in the long-term playbook. The trend is positive on revenue and strategic positioning, but investors should watch for margin recovery and CDMO breakeven timelines over the next 4-8 quarters.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
2,968
3,440
3,324
2,936
3,032
3,415
3,374
3,144
3,371
4,001
3,737
3,603
3,740
Expenses
2,579
2,693
2,616
2,534
2,423
2,662
2,615
2,752
2,632
3,080
2,909
3,086
2,974
Operating Profit
389
747
708
402
609
753
759
391
739
921
828
517
766
OPM %
13%
22%
21%
14%
20%
22%
23%
12%
22%
23%
22%
14%
20%
Other Income
66
6
42
76
120
134
93
146
149
104
90
65
153
Interest
30
30
25
27
29
28
36
28
30
35
42
54
47
Depreciation
72
74
70
83
80
79
85
112
88
94
95
106
100
PBT
353
648
655
367
619
780
731
396
771
896
781
423
772
Tax %
18%
5%
8%
17%
11%
10%
12%
18%
13%
13%
16%
40%
32%
Net Profit
288
615
604
304
550
702
641
322
668
779
653
251
521
EPS in Rs
23.98
51.9
49.76
24.55
45.6
57.6
52.34
25.58
55.56
63.99
53.19
19.78
43.49
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
3,674
4,905
5,688
6,401
7,357
8,344
8,865
10,634
11,599
12,668
12,965
14,712
15,081
Expenses
3,248
4,038
4,687
5,392
6,237
6,868
6,920
8,580
9,977
10,419
10,452
11,706
12,049
Operating Profit
427
866
1,001
1,009
1,120
1,476
1,945
2,054
1,622
2,249
2,512
3,007
3,032
OPM %
12%
18%
18%
16%
15%
18%
22%
19%
14%
18%
19%
20%
20%
Other Income
176
227
110
115
82
102
230
146
101
186
494
407
412
Interest
81
71
45
55
55
65
59
52
107
112
122
161
178
Depreciation
71
93
101
143
193
253
275
304
310
299
357
382
395
PBT
451
928
965
926
955
1,260
1,842
1,844
1,305
2,023
2,527
2,871
2,872
Tax %
13%
19%
6%
31%
19%
9%
12%
9%
23%
10%
12%
18%
—
Net Profit
392
752
905
638
774
1,149
1,618
1,680
1,007
1,811
2,215
2,351
2,204
EPS in Rs
32.75
62.02
74.61
52.77
63.61
94.26
133
138
82.31
150
181
193
180
Div. Payout %
12%
20%
20%
25%
25%
27%
23%
25%
61%
27%
25%
28%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
24
24
24
24
24
24
24
24
24
24
24
24
Reserves
2,975
3,668
4,444
4,840
5,415
6,137
7,353
8,614
9,021
10,288
11,961
13,796
Borrowings
1,306
658
659
998
944
1,616
1,707
2,668
1,397
1,418
1,381
2,047
Other Liabilities
986
1,184
1,440
1,803
1,824
2,169
2,435
2,763
3,315
3,844
4,325
4,991
Total Liabilities
5,291
5,534
6,568
7,664
8,208
9,946
11,519
14,069
13,757
15,575
17,691
20,858
Fixed Assets
1,374
1,450
1,797
2,284
2,530
2,908
2,793
2,902
2,683
2,873
2,852
3,871
CWIP
111
172
299
381
493
363
393
339
323
159
548
282
Investments
481
509
553
444
324
261
333
371
622
484
1,846
1,869
Other Assets
3,325
3,403
3,918
4,555
4,861
6,413
8,000
10,457
10,129
12,060
12,445
14,836
Total Assets
5,291
5,534
6,568
7,664
8,208
9,946
11,519
14,069
13,757
15,575
17,691
20,858
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
325
726
471
266
780
585
1,265
1,111
1,682
1,948
1,913
1,963
Investing
-235
205
-294
-351
-318
-737
-995
-1,433
120
-1,011
-1,288
-1,682
Financing
-52
-927
-138
85
-379
79
-272
380
-1,761
-1,145
-811
-503
Net Cash Flow
39
3
40
0
82
-73
-2
58
42
-207
-186
-222
Free Cash Flow
190
472
-163
-411
253
237
1,116
783
1,453
1,761
1,278
1,476
CFO/OP
101
107
73
47
92
59
86
73
121
105
96
86
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
52
42
46
62
62
72
66
65
67
65
69
74
Inventory Days
169
169
198
221
186
198
241
262
194
197
224
239
Days Payable
101
108
122
147
119
104
112
102
87
129
148
161
Cash Conversion Cycle
121
103
122
135
129
167
196
225
174
132
145
152
Working Capital Days
-52
13
34
40
55
44
48
31
66
135
123
123
ROCE %
12%
23%
21%
17%
16%
18%
22%
18%
14%
20%
20%
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Alkem Laboratories insights

71 extracted metrics + investor summaries across FY09–FY26.

Log in — free

Shareholding Pattern

Others0.21%Promot.49.70%FIIs10.42%Public17.04%DIIs22.63%As ofJun 2026

Documents

Frequently Asked Questions about Alkem Laboratories

What does Alkem Laboratories Ltd do?
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
Where is Alkem Laboratories Ltd (ALKEM) listed?
Alkem Laboratories Ltd trades as ALKEM on the NSE and under code 539523 on the BSE.
Which sector does Alkem Laboratories Ltd belong to?
Alkem Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Alkem Laboratories Ltd?
Alkem Laboratories Ltd has a market capitalisation of ₹60,655 Cr, which places it in the Large Cap band.
What is the PE ratio of Alkem Laboratories Ltd?
Alkem Laboratories Ltd trades at a PE ratio of 28.19, on earnings per share of ₹179.8, against a book value of ₹1,155.87 per share.
What is the 52-week high and low of Alkem Laboratories Ltd?
Over the last 52 weeks Alkem Laboratories Ltd has traded between ₹5,075 and ₹5,933.5.
Does Alkem Laboratories Ltd pay dividends?
Alkem Laboratories Ltd has a dividend yield of 1.03%.
What is the Return on Equity (ROE) of Alkem Laboratories Ltd?
Alkem Laboratories Ltd reported a return on equity of 16.40%. Its debt-to-equity ratio is 0.15.

Company Information

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)

Website alkemlabs.com
CEO Mr. Basudeo Narian Singh
Employees 18,785
Listed 2015-12-23
Face Value ₹ 2
Issued Size 11,95,65,000

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ALKEM.md for Alkem Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List